Vion Pharmaceuticals has extended its agreement with
SAFC Pharma for the manufacture of the API in Cloretazine, an anti-cancer drug currently in a Phase III trial in combination with Ara-C for relapsed acute myelogenous leukemia (AML), and a Phase II trial for elderly de novo poor-risk AML. The agreement extends the original 2003 supply agreement to 2009. Production for the API will continue to be provided by SAFC Pharma's high-potency manufacturing facility in Madison, WI.
SAFC president Frank Wicks commented, "Vion Pharmaceuticals' decision to extend its involvement with SAFC Pharma for Cloretazine API is a tribute to the consistency of high performance manufacturing at our Madison facility. The continuation of this appointment highlights our strengths as a premiere provider of process development and the production of complex, multi-step synthesis for highly potent and cytotoxic APIs."
Magazine
